Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

- - - 37,901

Total revenues 2,046,708 1,954,977 9,663,513 13,709,186

Operating expenses:

Research and

development 8,268,413 8,468,763 36,060,470 35,615,536

General and

administrative 2,820,543 3,372,108 13,569,578 12,254,892

Restructuring

charges 345,426 - 1,563,274 -

Total operating

expenses 11,434,382 11,840,871 51,193,322 47,870,428

Loss from operations (9,387,674) (9,885,894) (41,529,809) (34,161,242)

Interest income 661,381 898,786 2,971,666 3,394,751

Interest expense (57,631) (44,018) (209,885) (477,643)

Other income, net 5,949 1,124 7,108 6,873

Net loss $(8,777,975) $(9,030,002) $(38,760,920) $(31,237,261)

Basic and diluted

loss per share $(0.26) $(0.31) $(1.20) $(1.13)

Shares used in

computing basic and

diluted loss

per share 34,336,645 29,386,886 32,340,203 27,758,348


'/>"/>
SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... BUSAN, South Korea , May 23, 2013 ... collaboration with SillaJen, Inc., a private biotherapeutics and ... of targeted biological products for cancer, announced today ... antibodies in patients treated with the oncolytic and ... This research was published in the ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... New System to Streamline Process, Drive Value from ... Software Inc., a leading,provider of web-based employee performance ... been selected by Quiznos to provide a system,for ... is a,national chain with over 5000 franchise restaurants, ...
... Alimera Sciences,and pSivida Ltd (Nasdaq: PSDV ... have amended their license and collaboration agreement relating ... for,diabetic macular edema (DME), and other Medidur products. ... of Medidur FA from 50 to 80,percent in ...
... Million Distribution Contract from Anhui ... Huayuan Pharmaceutical Co., ... Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and,supplier ... today announced that the Company has been granted SFDA,approval ...
Cached Biology Technology:Quiznos Selects Halogen for Fresh Approach to Talent Management 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3
(Date:5/22/2013)... and engineers must join together in a major new ... a crisis in providing Earth,s people with clean water ... focus of a comment article in the current edition ... newsmagazine of the American Chemical Society (ACS), the world,s ... L. Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain ...
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
(Date:5/22/2013)... Adventitious changes in cellular DNA can endanger the whole ... cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report ... the double helix. , The DNA in our cells ... in our bodies. The instructions for this are encoded ... in DNA, the bases adenine (A), cytosine (C), guanine ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2
... a better understanding of why some pediatric acute lymphoblastic ... when existing clinical predictive criteria point towards a positive ... of Cancer Cell, is likely to facilitate development of ... for children with ALL. , Nearly 80% of children ...
... protect itself from HIV infection via the innate immune ... been shown to have anti-HIV activity. However, the mechanism ... been known. Appearing online on February 17 in advance ... the Journal of Clinical Investigation, Theresa Chang and colleagues ...
... products used to wrap or contain food and beverages ... can sometimes leach out of the plastic and migrate ... plastic is old or scratched. In two studies funded ... at Fox Chase Cancer Center in Philadelphia have demonstrated ...
Cached Biology News:Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia 2Compounds in plastic packaging act as environmental estrogens altering breast genes 2